洞察
Insights From Our Experts
Articles
Empowering Success: EVERSANA’s Value & Evidence Team Guides Clients Through CMS Drug Negotiations Under the Inflation Reduction Act
Authors: Chris Cameron, Kerise Clarke, Barkha Patel, Amanda Griffin In anticipation of CMS’s announcement of the first 10 drugs to be selected for negotiations through the Inflation Reduction Act on September 1, 2023, we partnered to…
CES 2024 Recap – How the Future of Healthcare Will Continue to Be Driven By Innovation & AI
CES 2024, the annual tech conference encompassing everything from cutting-edge gadgets to automotive marvels, healthcare innovations, and futuristic media, left a lasting impression. Amidst the buzz surrounding electric vehicles, transparent screens, and an abundance of massage…
Redefining Field Deployment – Bridging “Share of Voice” with “Share of Influence” for Lasting Impact
In the dynamic realm of pharmaceutical marketing, sales representatives and television commercials remain go-to strategies, skillfully weaving narratives that assure patients of a brand’s therapeutic benefits and persuade providers to alter prescribing habits. Despite their effectiveness,…
Uncovering Health Disparities: Exploring Social Determinants of Metastatic Prostate Cancer Survival
Author(s): Imtiaz A. Samjoo, MSc, PhD; Emily Rosta, MSc; Austin Lansing, MSc; Alexandra Hall, MPH Despite recent advancements in metastatic prostate cancer (mPC) treatment, prevention and care, progress has not equally manifested in all population groups.…
EVERSANA’s High-Quality HEOR Methods Recognized in Published Independent Review
A recent independent review conducted by Serret-Larmande and colleagues, featured in the Journal of Clinical Epidemiology, meticulously evaluated population-adjusted indirect comparisons published from 2010-2022. The analysis focused on assessing the reporting quality of methods and results…
Embarking on the Care Journey: Strategies for Engaging Patients Pre- and Post-Diagnosis
Navigating the healthcare system is a complex task for any patient, but it can be particularly tricky for those who are searching for more information on their symptoms, grappling with a recent diagnosis or looking for…
HemGenix Shines in Collaborative ITC Analysis: EVERSANA and CSL Behring Propel Gene Therapy to the Forefront in Hemophilia B Treatment
CSL Behring’s gene therapy for hemophilia B, HemGenix, was evaluated in the HOPE-B Phase III trial versus a basket of conventional FIX replacement products where it was found that the gene therapy reduced the annual bleed…
Impact of the European Union Medical Device Regulation Extension on Legacy Devices
Question: The European Union (EU) has extended the transition period for medical devices under the Medical Device Regulation (MDR) and removed the sell-off provisions for existing products. How do these changes impact you? Answer: On 7…
An Impactful Year for Global Regulation of Digital Health
2023 was a busy year with FDA and EU advancing key initiatives focused on AI/ML, cybersecurity, global harmonization, real-world evidence, and pharma companion apps…and more is coming in 2024. While 2023 brought its share of challenges…
Transforming Pharmaceutical Commercialization: Eight Key Insights for Success
Unlock the keys to successful pharmaceutical commercialization with our latest article: “Transforming Pharmaceutical Commercialization: Eight Key Insights for Success.” This insightful piece explores crucial, actionable strategies to transform your approach to drug launch. Here’s a glimpse…